Patients with B-cell Chronic Lymphocytic Leukemia, Rai Stage 0-II with indication for treatment by NCI Working Group Criteria or Rai Stage III or IV.

Patients must have received at least one prior purine analogue-based chemotherapy regimen.

ECOG Performance Status of 0, 1, or 2.

Female patients cannot be pregnant and must use birth control during the course of the study and for three weeks after the study ends.

Exclusion Criteria:

Prior treatment with ONTAK (DAB389IL-2) or DAB486IL-2.

Received any therapy for CLL within 35 days prior to study entry.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00055146

Locations

United States, California

Pacific Coast Hematology/Oncology Medical Group, Inc.

Fountain Valley, California, United States, 92708

UCSD School of Medicine

La Jolla, California, United States, 92093-0663

United States, Illinois

Rush-Presbyterian St. Luke's Cancer Center

Chicago, Illinois, United States, 60612

United States, New York

Weill Medical College of Cornell University/New York Presbyterian Hospital